WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan

ABSTRACT: Primary outcome(s): To evaluate the correlation between the efficacy or safety and the genetic polymorphism in patients with cetuximab plus irinotecan or panitumumab plus irinotecan therapy.

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2624189 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR